FDA Approves First Trial for Therapy Derived From Human Embryonic Stem Cells

Andrew Pollack at The New York Times reports that biotech company Geron has won approval for its Phase I trial of a hESC-derived therapy, which will treat spinal cord injuries:

Geron’s trial will involve 8 to 10 people with severe spinal cord injuries. The cells will be injected into the spinal cord at the injury site 7 to 14 days after the injury occurs, because there is evidence the therapy will not work for much older injuries. …Geron’s therapy involves using various growth factors to turn embryonic stem cells into precursors of neural support cells called oligodendrocytes, which are then injected into the spinal cord at the site of the injury.

He is careful to note that this is still a very early stage in the process, and that it could be years before the therapy, if successful, could be widely available. Geron officials quoted express tempered expectations, emphasizing that the trial will focus on safety.

Tags: ,

Comments on this article

One Response to “FDA Approves First Trial for Therapy Derived From Human Embryonic Stem Cells”

  1. Suzette Stack says:

    Ethically the question becomes when does life begin. We know that each of us has unique DNA. That the natural progression of development leads to old age and eventually death.
    When exactly does that development begin, and once begun when is it immoral to end that life in any way except naturally? I state that it is unethical to take a life no matter how early in that life’s development.

Leave a Comment

Please remember that the Science Progress Terms of Use do not allow promoting or endorsing any particular political party or candidate for office. Posts or comments that do this will be deleted. By clicking "Submit Comment" below, you acknowledge that you have read our Terms of Use agreement and agree to its terms.

Close
E-mail It